» Articles » PMID: 28388673

Proteolysis of Mature HIV-1 P6 Gag Protein by the Insulin-degrading Enzyme (IDE) Regulates Virus Replication in an Env-dependent Manner

Abstract

There is a significantly higher risk for type II diabetes in HIV-1 carriers, albeit the molecular mechanism for this HIV-related pathology remains enigmatic. The 52 amino acid HIV-1 p6 Gag protein is synthesized as the C-terminal part of the Gag polyprotein Pr55. In this context, p6 promotes virus release by its two late (L-) domains, and facilitates the incorporation of the viral accessory protein Vpr. However, the function of p6 in its mature form, after proteolytic release from Gag, has not been investigated yet. We found that the mature p6 represents the first known viral substrate of the ubiquitously expressed cytosolic metalloendopeptidase insulin-degrading enzyme (IDE). IDE is sufficient and required for degradation of p6, and p6 is approximately 100-fold more efficiently degraded by IDE than its eponymous substrate insulin. This observation appears to be specific for HIV-1, as p6 proteins from HIV-2 and simian immunodeficiency virus, as well as the 51 amino acid p9 from equine infectious anaemia virus were insensitive to IDE degradation. The amount of virus-associated p6, as well as the efficiency of release and maturation of progeny viruses does not depend on the presence of IDE in the host cells, as it was shown by CRISPR/Cas9 edited IDE KO cells. However, HIV-1 mutants harboring IDE-insensitive p6 variants exhibit reduced virus replication capacity, a phenomenon that seems to depend on the presence of an X4-tropic Env. Furthermore, competing for IDE by exogenous insulin or inhibiting IDE by the highly specific inhibitor 6bK, also reduced virus replication. This effect could be specifically attributed to IDE since replication of HIV-1 variants coding for an IDE-insensitive p6 were inert towards IDE-inhibition. Our cumulative data support a model in which removal of p6 during viral entry is important for virus replication, at least in the case of X4 tropic HIV-1.

Citing Articles

Altered Surface Expression of Insulin-Degrading Enzyme on Monocytes and Lymphocytes from COVID-19 Patients Both at Diagnosis and after Hospital Discharge.

Gonzalez-Casimiro C, Arribas-Rodriguez E, Fiz-Lopez A, Casas J, Gutierrez S, Telleria P Int J Mol Sci. 2022; 23(19).

PMID: 36232381 PMC: 9570012. DOI: 10.3390/ijms231911070.


Inhibition of Insulin Degrading Enzyme to Control Diabetes Mellitus and its Applications on some Other Chronic Disease: a Critical Review.

Azam M, Wahiduzzaman M, Reyad-Ul-Ferdous M, Islam M, Roy M Pharm Res. 2022; 39(4):611-629.

PMID: 35378698 DOI: 10.1007/s11095-022-03237-7.


Quantitative NMR Study of Insulin-Degrading Enzyme Using Amyloid-β and HIV-1 p6 Elucidates Its Chaperone Activity.

Ramaraju B, Nelson S, Zheng W, Ghirlando R, Deshmukh L Biochemistry. 2021; 60(33):2519-2523.

PMID: 34342986 PMC: 8895387. DOI: 10.1021/acs.biochem.1c00342.


HIV-1 Gag Recruits Oligomeric Vpr via Two Binding Sites in p6, but Both Mature p6 and Vpr Are Rapidly Lost upon Target Cell Entry.

Wanaguru M, Bishop K J Virol. 2021; 95(17):e0055421.

PMID: 34106747 PMC: 8354229. DOI: 10.1128/JVI.00554-21.


An Autoantigen-ome from HS-Sultan B-Lymphoblasts Offers a Molecular Map for Investigating Autoimmune Sequelae of COVID-19.

Wang J, Zhang W, Roehrl V, Roehrl M, Roehrl M bioRxiv. 2021; .

PMID: 33851168 PMC: 8043459. DOI: 10.1101/2021.04.05.438500.


References
1.
Schubert U, Clouse K, Strebel K . Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes. J Virol. 1995; 69(12):7699-711. PMC: 189711. DOI: 10.1128/JVI.69.12.7699-7711.1995. View

2.
Gutierrez A, Balasubramanyam A . Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management. Endocrine. 2011; 41(1):1-10. PMC: 3417129. DOI: 10.1007/s12020-011-9565-z. View

3.
Andreoni M, Sarmati L, Ercoli L, Nicastri E, Giannini G, Galluzzo C . Correlation between changes in plasma HIV RNA levels and in plasma infectivity in response to antiretroviral therapy. AIDS Res Hum Retroviruses. 1997; 13(7):555-61. DOI: 10.1089/aid.1997.13.555. View

4.
Salter R, Howell D, Cresswell P . Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics. 1985; 21(3):235-46. DOI: 10.1007/BF00375376. View

5.
Bruns K, Fossen T, Wray V, Henklein P, Tessmer U, Schubert U . Structural characterization of the HIV-1 Vpr N terminus: evidence of cis/trans-proline isomerism. J Biol Chem. 2003; 278(44):43188-201. DOI: 10.1074/jbc.M305413200. View